LloydsPharmacy supports Liverpool John Moores University to launch new post-graduate course

Centre for Pharmacy Innovation logo

The Collaborative Centre for Pharmacy Innovation (CCfPI) has launched a new post-graduate programme titled: Clinical Pharmacy for Primary and Interface Care, which is available at Liverpool John Moores University (LJMU).

The CCfPI was established in 2014 as research collaboration between LJMU, The Royal Liverpool and Broadgreen University Hospitals Trust and LloydsPharmacy. The collaborative Centre aims to be a hub of excellence, focusing on clinical pharmacy practice research and the education and training of pharmacists and pharmacy technicians.

This new course, which is aimed at qualified pharmacists already working in communities, hospital outpatient departments and general medical practices, has been designed to enhance the clinical capabilities of professionals in primary and interface care settings.

Head of operations and speciality service design at LloydsPharmacy, Adam Crampsie comments: “We’re really excited to see our CCfPI partnership take another big step. This programme is all about equipping pharmacists with the knowledge and skills to deliver more effective care in primary and secondary environments. We have 11 of our own LloydsPharmacy colleagues signed up to take the course.”

Clinical Pharmacy for Primary and Interface Care is a part time programme which means students can continue to work in their practices and apply the new skills while they learn. The full Masters (MSc) course runs over three years, but for students who wish to stage their development it is also offered as a one year Postgraduate Certificate or two year Postgraduate Diploma.

The first cohort of students started in April 2017 and has now been assigned a clinical liaison tutor (CLT). The CLT is in place to support students through regular contact sessions and by offering support and guidance throughout the course.

Adam continues: “Through our Centre for Pharmacy Innovation, pharmacists have access to an incredible bank of expertise. Our forward-thinking collaboration means students can learn from three major organisations that are passionate about improving patient care across the board.”

LloydsPharmacy has worked with The Royal Liverpool and Broadgreen University Hospitals Trust since 2009. The clinical success of this partnership, which involved LloydsPharmacy providing hospital outpatient dispensary services, then, inspired the academic connection with Liverpool John Moores University.

Charles Morecroft, Professor of pharmacy education and professional practice at LJMU’s Faculty of Science says: “Our Innovation Centre aims to encourage and inspire inter-professional, interdisciplinary and inter-sector integration to advance the standards of excellence in the delivery of health and social care.

“Through this course, we’re hoping to prepare students for the more clinical future of pharmacy in a wide range of sectors.”

Adam Crampsie continues: “This is where we think the future of clinical pharmacy is going. Our amazing profession has been through some challenging times recently, but we must continue to move forward and develop innovations like this that help to enhance our role in healthcare.”

Professor Alison B Ewing, clinical director of pharmacy at Royal Liverpool and Broadgreen University Hospitals NHS Trust says: “Clinical Pharmacy for Primary and Interface Care is the first course of its kind and is completely unique to the market. This is another exciting initiative, born out of our CCfPI partnership that truly demonstrates our potential to help shape the future of our profession.”

 

ENDS

 

Please direct any media enquiries to the Celesio UK Corporate PR team:

Claire Salmons – Claire.salmons@celesio.co.uk

Joe Scholes – joe.scholes@celesio.co.uk

024 7662 5530

 

Notes to editors

About the Centre for Pharmacy Innovation

A tripartite relationship with LJMU (specifically the School of Pharmacy and Biomolecular Sciences), Royal Liverpool Broadgreen University Hospital NHS Trust and Celesio UK (specifically LloydsPharmacy) is designed as a centre of excellence focusing on clinical pharmacy practice research, and the education and training of pharmacists and pharmacy technicians.

Changing the way that pharmaceutical care is delivered across the interface between primary and secondary care would improve the patient experience, enhance the role of the community pharmacist and potentially save the NHS money by improving the quality of care provided. The CCfPI aims to research and explore this area which a view of helping to shape the future of the pharmacy profession.

 

About Celesio UK, including LloydsPharmacy

Celesio UK is a leading provider of integrated healthcare services to the NHS specialising in medicines, pharmaceutical care and primary care patient services.

With almost 25,000 employees, more than 1,750 community pharmacies, a UK-wide logistics network and dispensing in excess of 150 million items a year, Celesio UK works in partnership with the NHS, community pharmacies and medicines manufacturers to help UK citizens live longer, healthier and more positive lives. Celesio UK provides customers, the NHS and patients with high levels of service, value, efficiency and innovation.

Celesio UK comprises LloydsPharmacy, AAH Pharmaceuticals, Evolution Homecare, LloydsPharmacy Clinical Homecare, Masta, Online Doctor and Betterlife.

With strong brands and about 37,000 employees, Celesio group is active in 13 European countries (thereof with own operations in ten countries; Celesio manages operations in two countries and participates in a joint venture in one country). Every day, the company serves over 2 million customers – at more than 2,150 pharmacies of its own, at about 300 managed pharmacies and at over 4,500 participants in the brand partnership schemes. With 107 wholesale branches in Europe, Celesio supplies more than 50,000 pharmacies and hospitals every day with up to 130,000 pharmaceutical products.

McKesson Corporation, San Francisco, USA, is the majority shareholder in Celesio AG. The company acquired more than 75 percent of Celesio AG shares in February 2014. McKesson provides solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services.

McKesson is a Fortune-500 company and currently ranking #5.

 

About The Royal Liverpool and Broadgreen University Hospitals NHS Trust

The Royal Liverpool and Broadgreen University Hospitals NHS Trust is one of the largest and busiest hospital trusts in the North of England, with an annual budget exceeding £400 million. It delivers services across two sites and three hospitals, the Royal Liverpool University Hospital, Broadgreen Hospital and Liverpool University Dental Hospital, and employs more than 5,500 people.

Each year the Trust sees more than half a million people in its outpatient department and deals with around 150,000 emergency patients and day case admissions. It is one of the top teaching trusts in the UK with well-established links to the University of Liverpool, Liverpool John Moores University and international institutions. To find out more about the Trust, visit www.rlbuht.nhs.uk.

 

About Liverpool John Moores University

Liverpool John Moores University is one of the leading research-active new universities in the UK, combining areas of world-leading, international and national excellence in research.

The School of Pharmacy and Biomolecular Sciences is one of the oldest providers of Pharmacy education in Europe, and has been delivering industry-relevant courses since 1849. It offers both outstanding facilities and great expertise through its research with funding obtained from a wide variety of sources, including directly from industrial companies, reflecting the applied aspects of the subjects. Additionally, international collaboration with other university research groups in China, France, Spain, Slovakia, Iran, Thailand, and many other countries is also a strong feature of the School’s research activities. http://www.ljmu.ac.uk/pbs/